Assignee
ANAVEX LIFE SCIENCES CORP
US·31 granted patents·11 pending applications·46 citations·filing 2013–2025
Top patents by PatentIndex Score
42 records- 0195US11446275B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Sep 20, 2022·3 cites·20 claims
- 0294US11813242B2A2-73 as a therapeutic for insomnia, anxiety, and agitationANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Nov 14, 2023·2 cites·14 claims
- 0392US11839600B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Dec 12, 2023·1 cites·20 claims
- 0490US10813907B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Oct 27, 2020·4 cites·3 claims
- 0590US10507196B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2017·Granted Dec 17, 2019·8 cites·8 claims
- 0689US11337953B2A2-73 as a therapeutic for insomnia, anxiety, and agitationANAVEX LIFE SCIENCES CORP·Filed 2017·Granted May 24, 2022·3 cites·10 claims
- 0787US11622955B2Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2018·Granted Apr 11, 2023·2 cites·22 claims
- 0887US10888543B2Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Jan 12, 2021·4 cites·24 claims
- 0984US12285403B2A2-73 as a therapeutic for insomnia, anxiety and agitationANAVEX LIFE SCIENCES CORP·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 1084US9750746B2ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotectionANAVEX LIFE SCIENCES CORP·Filed 2013·Granted Sep 5, 2017·7 cites·2 claims
- 1183US12533352B2Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofANAVEX LIFE SCIENCES CORP·Filed 2024·Granted Jan 27, 2026·0 cites·19 claims
- 1283US2024066003A1Neurodevelopmental disorder therapyANAVEX LIFE SCIENCES CORP·Filed 2023·Application pending·0 cites
- 1382US12594256B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2023·Granted Apr 7, 2026·0 cites·20 claims
- 1481US10966952B2Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositionsANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Apr 6, 2021·1 cites·15 claims
- 1581US2025120938A1Enantiomers of a2-73, analogues, and sigma agonist activityANAVEX LIFE SCIENCES CORP·Filed 2024·Application pending·0 cites
- 1680US12280034B2Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Apr 22, 2025·0 cites·21 claims
- 1780US11661405B2Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositionsANAVEX LIFE SCIENCES CORP·Filed 2021·Granted May 30, 2023·1 cites·4 claims
- 1880US11071723B2Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2018·Granted Jul 27, 2021·2 cites·14 claims
- 1978US2025064772A1Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2024·Application pending·0 cites
- 2077US9180106B2Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activityANAVEX LIFE SCIENCES CORP·Filed 2014·Granted Nov 10, 2015·6 cites·16 claims
- 2176US2025319057A1A2-73 as a therapeutic for insomnia, anxiety and agitationANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 2275US10413519B2Crystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositionsANAVEX LIFE SCIENCES CORP·Filed 2016·Granted Sep 17, 2019·1 cites·18 claims
- 2373US11896590B2Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Feb 13, 2024·0 cites·20 claims
- 2473US2025115566A1A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2024·Application pending·0 cites
- 2572US12180174B2A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Dec 31, 2024·0 cites·7 claims
- 2671US12138240B2Treatment of cardiac dysfunctionANAVEX LIFE SCIENCES CORP·Filed 2021·Granted Nov 12, 2024·0 cites·16 claims
- 2771US11690821B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2020·Granted Jul 4, 2023·0 cites·20 claims
- 2871US2023278973A1Crystal forms of tetrahydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine, processes of making such forms, and their pharmaceutical compositionsANAVEX LIFE SCIENCES CORP·Filed 2023·Application pending·0 cites
- 2971US2025281447A1Sigma-1 receptor agonist systolic blood pressure therapyANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 3069US10426754B2Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's diseaseANAVEX LIFE SCIENCES CORP·Filed 2017·Granted Oct 1, 2019·1 cites·25 claims
- 3168US11498908B2A2-73 crystalline polymorph compositions of matter and methods of use thereofANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Nov 15, 2022·0 cites·29 claims
- 3266US2025325514A1Optimized sigma-1 agonist method of responder selection and treatmentANAVEX LIFE SCIENCES CORP·Filed 2025·Application pending·0 cites
- 3365US10933062B2Analgesic therapeutic and method, 1-(3-4(((1 R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Mar 2, 2021·0 cites·21 claims
- 3463US12208079B2Enantiomers of A2-73, analogues, and sigma agonist activityANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Jan 28, 2025·0 cites·4 claims
- 3563US2024417798A1Therapy selection and treatment of neurodegenerative disordersANAVEX LIFE SCIENCES CORP·Filed 2022·Application pending·0 cites
- 3662US12558340B2ANAVEX2-73 for the treatment of genetic neurodevelopmental disordersANAVEX LIFE SCIENCES CORP·Filed 2022·Granted Feb 24, 2026·0 cites·7 claims
- 3760US12383526B2Optimized sigma-1 agonist method of responder selection and treatmentANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Aug 12, 2025·0 cites·8 claims
- 3858US11103478B2Anavex2-73 for the treatment of alzheimer's diseaseANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Aug 31, 2021·0 cites·11 claims
- 3958US2017360798A1Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotectionANAVEX LIFE SCIENCES CORP·Filed 2017·Application pending·0 cites
- 4052US2022249427A1Anavex2-73 for the treatment of genetic neurodevelopmental disordersANAVEX LIFE SCIENCES CORP·Filed 2020·Application pending·0 cites
- 4150US11617734B2Enantiomers of A2-73, analogues, and sigma agonist activityANAVEX LIFE SCIENCES CORP·Filed 2016·Granted Apr 4, 2023·0 cites·19 claims
- 4241US10441563B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2015·Granted Oct 15, 2019·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when ANAVEX LIFE SCIENCES CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →